Insmed Incorporated , a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced that Sara Bonstein will step down as Chief Financial Officer (CFO). Ms. Bonstein will continue to serve as CFO until October 30, 2026, to ensure a smooth transition through the Company's reporting of its third-quarter 2026 financial results and she will participate in the earnings call on Thursday, October 29, 2026. Insmed has commenced a search to identify the Company's next CFO.
"We are grateful for Sara's many contributions over the past almost seven years and her dedicated leadership overseeing our finance organization during a time when Insmed raised more than $4.2 billion in capital," said Will Lewis, Chair and Chief Executive Officer of Insmed. "We are now well positioned to reach cash flow positivity next year with what we view as a clear path toward sustained top-line growth and bottom-line profitability."
"Serving as Insmed's CFO has been a privilege of my career," said Ms. Bonstein. "I am thankful for our team and all we achieved together during my time with the Company. I am confident in Insmed's future, especially given our successful launch of BRINSUPRI coupled with our exciting pipeline. After considerable reflection, now is an ideal time for me to pursue my ambition for a broader leadership role."
Lewis continued, "Sara has been a steadfast partner in building Insmed into the company we are today, and we wish her well as she pursues her next leadership opportunity. Insmed has undergone a major transformation in recent years to become a global diversified biotech company with a robust portfolio of first- or best-in-class therapies with the potential to deliver meaningful impact for patients with serious diseases. With BRINSUPRI and ARIKAYCE on track to deliver meaningful revenue this year, and with substantial growth expected in the years ahead through our commercial portfolio and diverse therapeutic pipeline, we remain focused on delivering on our long-term ambitions. We are committed to ensuring our finance operations continue supporting Insmed's success in our next phase of growth, and we have partnered with a leading executive search firm to identify our next CFO."